[The role of radiotherapy in the treatment of malignant lymphoma].
Eighty-four patients with malignant lymphoma in N.I.R.S., whose five-year survival was evaluated, were divided into two groups. The first one was treated mainly with irradiation between 1961 and 1972 (n = 36) and the second one mainly with anticancer drugs thereafter (n = 48). The survival of the second group was significantly superior to the first one: 60% vs 20% in the five-year survival rate of Hodgkin lymphoma (HL) and 40% vs 20% in non-Hodgkin lymphoma (NHL). These results were due to the systemic application of chemotherapy in the second group. On the other hand, 40% of the patients with NHL in the head and neck at stages I + II and who received radiotherapy alone survived. Through a detailed analysis of these data, the role of radiotherapy in the treatment of malignant lymphoma was discussed.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D004351:Drug Resistance; D005260:Female; D006258:Head and Neck Neoplasms / Q000628:therapy; D006689:Hodgkin Disease / Q000532:radiotherapy; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012306:Risk